Singlera Genomics signed a research and distribution agreement with EU‑based Pure Medical to commercialize its cell‑free DNA mTitan and mGuard methylation‑based cancer detection assays across several European countries. The companies will also collaborate with hospitals and universities on related research studies. Singlera said the partnership supports its European expansion strategy for inexpensive early cancer detection and monitoring. The agreement follows Singlera’s recent research collaboration with the University of Pittsburgh on a pancreatic cancer test. Qiang Liu, Singlera’s chief operating officer, framed the deal as a step to accelerate clinician access to methylation‑based diagnostics for faster detection, diagnosis and treatment of cancer.